← Search another drug
PatientPulse · by PatientPartner
Qulipta atogepant
High confidence
Approximately 50 public pages analyzed including review site aggregations (~380 individual ratings), patient forum threads, and medically reviewed blog content published 2022 to 2026.
Executive intelligence
The signal that moves starts & adherence
62%Positive sentiment in discussion
6,135FDA adverse-event reports
34%Flagged serious
87%Reports name female patients
Cost access is the single biggest adherence threat: patients who call Qulipta a "miracle drug" are simultaneously reporting they had to stop because insurance denied coverage or the discount card ran out.
- Qulipta generates some of the most emotionally intense efficacy testimonials in migraine care, with patients describing freedom from decades of daily attacks after exhausting every prior option.
- Insurance denial and out-of-pocket costs above $800 per month are the dominant drop-off triggers, causing patients to abandon a therapy they describe as life-changing.
- Constipation is the most-mentioned side effect in patient reviews at roughly 16% of conversations, but most high-responders stay on therapy and manage it with stool softeners, fiber, and hydration rather than discontinuing.
- Timing of the daily dose (morning vs. evening) is a patient-discovered self-management hack that significantly reduces sleep disruption and vivid dreams, yet is rarely proactively communicated at initiation.